Oaktree Capital Management
Oaktree Capital Management is a privately owned investment manager specializing in alternative investment strategies.
Business Model:
Revenue: $709.5M
Employees: 1,001-5,000
Rankings
Industries / Tags:
Detailed Oaktree Capital Management Information
Oaktree Capital Management was acquired by
Brookfield Asset Management.
The acquisition happend on 2019-03-13.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 333 South Grand Avenue
City: Los Angeles
State: CA
Zip: 90071
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$36B
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
320,238Website Global Rank
183,165Website Monthly Traffic
Twitter Followers
Description
Oaktree’s mission is to provide highly professional management with a primary emphasis on risk control in a limited number of sophisticated investment specialties. Oaktree specializes in less efficient markets and alternative investments, and has extensive experience, an enviable track record, broad product range and substantial assets under management. They are dedicated to the achievement of consistent and superior performance without high risk. Their ultimate objective is investment success, the fruits of which are shared by Oaktree’s clients and personnel.
Contact Phone:
+12138306300
Contact Email:
Oaktree Capital Management went public on 4/12/2012 on the NYSE
Listed Exchange:
NYSE
IPO Date:
4/12/2012
IPO Valuation:
$1B
Ticker Symbol:
OAK
IPO Price:
$43/share
Amount Raised:
$380M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 9/2021 | Priority Power Management | Private Equity Round | 250M |
| 11/2020 | REEF | Private Equity Round | 700M |
| 6/2019 | cure.fit | Series D | 120M |
| 4/2022 | BioXcel Therapeutics | Post-IPO Debt | 135M |
| 7/2020 | M3M India Limited | Debt Financing | 76M |
| 12/2020 | BKV Corporation | Venture Round | 100M |
| 12/2021 | SiO2 Materials Science | Debt | 205M |
| 12/2020 | brumbrum | Debt Financing | 65M |
| 8/2020 | Fortress Biotech | Post-IPO Debt | 60M |
| 9/2016 | ICICI Prudential Life Insurance | Private Equity Round | 0 |
| 3/2021 | SumUp | Debt Financing | 0 |
| 6/2021 | Primary Wave | Private Equity Round | - |
| 7/2016 | Array Technologies | Seed Round | - |
| 3/2021 | NN | Post-IPO Equity | 265M |
| 10/2011 | Panrico SA | Debt Financing | - |
| 10/2021 | Thrasio | Series D | 0 |
| 11/2016 | Sterling Lumber Company | Venture Round | - |
| 1/2022 | Unblocked | Seed Round | 0 |
| 3/2016 | ProService Finteco | Private Equity Round | - |
| 7/2018 | cure.fit | Series C | 120M |
| 4/2014 | Enplug | Seed Round | 0 |
| 3/2021 | RumbleON | Post-IPO Equity | 280M |
| 9/2020 | Zzoomm Full Fibre Broadband | Series B | 128.7M |
| 10/2018 | Montrose | Private Equity Round | - |
| 2/2018 | Kudu Investment Management | Funding Round | 0 |
| 6/2004 | Infraworks | Series B | 7.5M |
| 4/2021 | Thrasio | Series C | 0 |
| 9/2020 | Universal Plant Services | Secondary Market | - |
| 2/2021 | Thrasio | Series C | 750M |
| 10/2016 | SunOpta | Post-IPO Equity | 85M |
| 10/2022 | scPharmaceuticals | Post-IPO Debt | 100M |
| 4/2015 | ezbob | Debt Financing | 45.2M |
| 4/2020 | SunOpta | Post-IPO Equity | 0 |
| 1/2014 | Ten K Solar | Venture Round | 0 |
| 4/2022 | BioXcel Therapeutics | Post-IPO Equity | 5M |
| 12/2021 | Cvent | Post-IPO Equity | 0 |
| 10/2018 | Blue Sky Private Equity | Post-IPO Debt | 35.9M |
| 11/2012 | Pulse Electronics | Post-IPO Equity | 102.7M |
| 8/2021 | Environmental 360 Solutions E360S | Venture Round | - |
| 7/2019 | Singular | Venture Round | - |
| 9/2019 | Mission Lane | Debt Financing | 300M |
| 6/2019 | Costa Edutainment | Secondary Market | 45.5M |
| 10/2018 | Assembled Brands | Funding Round | 100M |
| 11/2021 | Elevate Brands | Venture Round | 0 |
| 2/2021 | Win Brands Group | Equity | 50M |
| 3/2016 | FortiFi | Series A | 75M |
| 1/2021 | Thrasio | Debt Financing | 0 |
| 7/2017 | DDH1 | Venture Round | - |
| 12/2020 | System One | Private Equity Round | - |
| 12/2021 | HealthCare.com | Series C | 0 |
| 3/2018 | Proserv | Private Equity Round | 50M |
| 6/2019 | SHINE Medical Technologies | Debt | 50M |
| 6/2016 | Tribes | Venture Round | - |
| 2/2022 | b atomic | Seed | 1M |
| 12/2019 | Marinus Pharmaceuticals | Equity | 30M |
| 10/2021 | Mission Lane | Debt Financing | 150M |
| 3/2016 | ezbob | Series C | 28.8M |
| 5/2021 | Marinus Pharmaceuticals | Post-IPO Debt | 45M |
| 1/2022 | ABC Technologies | Post-IPO Equity | 269.5M |
| 3/2022 | Impel NeuroPharma | Post-IPO Debt | 50M |
| 3/2013 | Charter Communications | Post-IPO Equity | - |
| 4/2020 | Airbnb | Debt Financing | 1B |
| 2/2022 | Draslovka | Private Equity Round | 0 |
| 12/2021 | Montana Renewables | Debt Financing | 300M |
| 4/2022 | BioXcel Therapeutics | Post-IPO Debt | 0 |
| 4/2022 | BioXcel Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | Marinus Pharmaceuticals | Post-IPO Debt | 0 |
| 3/2022 | Impel NeuroPharma | Post-IPO Debt | 0 |
| 2/2022 | b atomic | Seed Round | 0 |
| 2/2022 | Draslovka | Private Equity Round | 0 |
| 1/2022 | Unblocked | Seed Round | 0 |
| 1/2022 | ABC Technologies | Post-IPO Equity | 0 |
| 12/2021 | SiO2 Materials Science | Debt Financing | 0 |
| 12/2021 | HealthCare.com | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
